Female and male differences in AIDS diagnosis rates among people who inject drugs in large U.S. metro areas from 1993 to 2007

Annals of Epidemiology

Volumn 25, Issue 4, 2015, Pages 218-225

  West, Brooke S ^a   Pouget, Enrique R ^b   Tempalski, Barbara ^b   Cooper, Hannah L F ^c   Hall, H Irene ^d   Hu, Xiaohong ^d   Friedman, Samuel R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^c EMORY UNIVERSITY   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

AIDS; Gender; Health status disparities; Injection drug use

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; DRUG ABUSE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH DISPARITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INJECTION DRUG USE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; UNITED STATES; COMPLICATION; HIV INFECTIONS; MIDDLE AGED; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; URBAN POPULATION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES; URBAN POPULATION; YOUNG ADULT;

EID: 84925233704     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2015.01.006     Document Type: Article

References (33)

1. Diagnoses of HIV infection in the United States and dependent areas. HIV Surveill Rep 2011, Vol. 23:1-84. Center for Disease Control and Prevention.
2. AIDS associated with injecting-drug use-United States, 1995. MMWR 1996, 45(19):392-398. Center for Disease Control and Prevention.
3. Tempalski B., Pouget E., Cleland C., Brady J., Cooper H., Hall H., et al. Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992-2007. PLoS One 2013, 8(6):e64789.
4. Tempalski B., Lieb S., Cleland C.M., Cooper H., Brady J.E., Friedman S.R. HIV prevalence rates among injection drug users in 96 large US metropolitan areas, 1992-2002. JUrban Health 2009, 86(1):132-154.
5. Friedman S.R., Lieb S., Tempalski B., Cooper H., Keem M., Friedman R., et al. HIV among injection drug users in large US metropolitan areas, 1998. JUrban Health-Bulletin of the New York Academy of Medicine 2005, 82(3):434-445.
6. Friedman S.R., West B.S., Pouget E.R., Hall H.I., Cantrell J., Tempalski B., et al. Metropolitan social environments and pre-HAART/HAART era changes in mortality rates (per 10,000 adult residents) among injection drug users living with AIDS. PLoS One 2013, 8(2):e57201.
7. Pouget E.R., West B.S., Tempalski B., Cooper H.L.F., Hall H.I., Hu X., et al. Persistent racial/ethnic disparities in AIDS diagnosis rates among people who inject drugs in US metropolitan areas, 1993-2007. Public Health Rep 2014, 129(3):267-279.
8. Kaplan J.E., Hanson D., Dworkin M.S., Frederick T., Bertolli J., Lindegren M.L., et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000, 30(Suppl. 1):S5-S14.
9. Walensky R.P., Paltiel A.D., Losina E., Mercincavage L.M., Schackman B.R., Sax P.E., et al. The survival benefits of AIDS treatment in the United States. JInfect Dis 2006, 194(1):11-19.
10. Standards for defining metropolitan and micropolitan statistical areas. Fed Regist 2000, 65:8228-82238. Office of Management and Budget.
11. Friedman S.R., Tempalski B., Cooper H., Perlis T., Keem M., Friedman R., et al. Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users. JUrban Health 2004, 81(3):377-400.
12. Holmberg S.D. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health 1996, 86(5):642-654.
13. Brady J.E., Friedman S.R., Cooper H.L., Flom P.L., Tempalski B., Gostnell K. Estimating the prevalence of injection drug users in the U.S. and in large U.S. metropolitan areas from 1992 to 2002. JUrban Health 2008, 85(3):323-351.
14. Martin J., Hamilton B., Sutton P., Ventura S., Menacker F., Kirmeyer S., et al. Births: final data for 2006. Natl Vital Stat Rep 2009, 57(7):1-104.
15. Kleinman J., Kiely J. Infant mortality. Health People 2000 Stat Notes 1991, 1(2):1-10.
16. Hoover K., Bohm M., Keppel K. Measuring disparities in the incidence of sexually transmitted diseases. Sex Transm Dis 2008, 35(12 Suppl):S40-S44.
17. IBM SPSS statistics for Windows. Version 20.0 ed 2010, IBM Corp, IBM Corp., Armonk, NY, Released.
18. Quinn T.C., Overbaugh J. HIV/AIDS in women: an expanding epidemic. Science 2005, 308(5728):1582-1583.
19. Grigoryan A., Hall H.I., Durant T., Wei X. Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996-2004. PLoS One 2009, 4(2):e4445.
20. Barash E.T., Hanson D.L., Buskin S.E., Teshale E. HIV-infected injection drug users: health care utilization and morbidity. JHealth Care Poor Underserved 2007, 18(3):675-686.
21. Cescon A., Cooper C., Chan K., Palmer A., Klein M., Machouf N., et al. Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort. HIV Med 2011, 12(6):352-360.
22. Wood E., Kerr T., Tyndall M.W., Montaner J.S. Areview of barriers and facilitators of HIV treatment among injection drug users. AIDS 2008, 22:1247-1256.
23. Zierler S., Krieger N. Reframing women's risk: social inequalities and HIV infection. Annu Rev Public Health 1997, 18(1):401-436.
24. Eisenman D., Bogart L.M., Bird C.E., Collins R.L., Golinelli D., Fremont A., et al. Differential diffusion of HIV technologies by gender: the case of highly active antiretroviral therapy. AIDS patient care and STDS 2007, 21(6):390-399.
25. Gebo K.A., Fleishman J.A., Conviser R., Reilly E.D., Korthuis P.T., Moore R.D., et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. JAcquir Immune Defic Syndr 2005, 38(1):96-103.
26. Giordano T.P., White C.A., Sajja P., Graviss E.A., Arduino R.C., Adu-Oppong A., et al. Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. JAcquir Immune Defic Syndr 2003, 32(4):399-405.
27. Hirschhorn L.R., McInnes K., Landon B.E., Wilson I.B., Ding L., Marsden P.V., et al. Gender differences in quality of HIV care in Ryan White CARE Act-funded clinics. Womens Health Issues 2006, 16(3):104-112.
28. King W.D., Minor P., Ramirez Kitchen C., Ore L.E., Shoptaw S., Victorianne G.D., et al. Racial, gender and geographic disparities of antiretroviral treatment among US Medicaid enrolees in 1998. JEpidemiol Community Health 2008, 62(9):798-803.
29. Reif S., Whetten K., Thielman N. Association of race and gender with use of antiretroviral therapy among HIV-infected individuals in the Southeastern United States. South Med J 2007, 100(8):775-781.
30. Lemly D.C., Shepherd B.E., Hulgan T., Rebeiro P., Stinnette S., Blackwell R.B., et al. Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. JInfect Dis 2009, 199(7):991-998.
31. Poundstone K.E., Chaisson R.E., Moore R.D. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001, 15(9):1115-1123.
32. Wood E., Kerr T., Zhang R., Guillemi S., Palepu A., Hogg R., et al. Poor adherence to HIV monitoring and treatment guidelines for HIV-infected injection drug users. HIV Med 2008, 9(7):503-507.
33. Current trends update: impact of the expanded AIDS surveillance case definition for adolescents and adults on case reporting-United States, 1993. MMWR 1994, 43(09):160-161. Center for Disease Control and Prevention, 167-170.